Pharmx Technologies Limited · ASX:PHX
Pharmx Technologies — Corum Group — Shareholder Meeting (November 2021)
20 slides from Pharmx Technologies's shareholder meeting presentation, Nov 24, 2021
Slide 1: Chairman's Address to the Annual General Meeting
Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au Chairman’s Address to the Annual General Meeting 24 NOVEMBER 2021 2021 has been a year of consolidation for the business and preparing it for future growth following the myriad of activities in 2
Slide 2: Chairman's Address (continued)
Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au We also recently signed an agreement with Go Vita to provide both retail software as well as utilising the PharmX platform. This is a significant development as it shows that Corum can be competi
Slide 3: CEO Address
Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au CEO Address It is my pleasure to present to you today and thank you everyone for joining us. Firstly, and importantly, I would like to acknowledge our customers, the pharmacy groups and pharmacis
Slide 4: Create new competitive advantages via the PharmX platform
Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au Create new competitive advantages for Corum via the PharmX platform We have a clear strategy for PharmX that we have been pursuing this year: 1. Increasing the range of direct suppliers available
Slide 5: PharmX investment and retail group agreements
Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au The investment in PharmX has continued. We are growing the number of suppliers on the platform and increasing the use of the service by pharmacies. To accelerate this growth we have removed some
Slide 6: Acquisition strategy and summary
Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au specials, or as an entry-level ERP. To augment our organic growth initiatives, we have recently engaged TMT Partners as corporate advisors to actively seek merger and acquisition opportunities. T
Slide 7: Corum Group Limited Annual General Meeting
Corum Group Limited Annual General Meeting Chairman Nick England CEO Julian Sallabank November 24th 2021
Slide 8: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation has been prepared by Corum Group Limited (COO or the assurance that the results, performance or achievements expressed or implied by Company or Corum). It should not be considered as an offer or invitation to the forward-looking statements contained in
Slide 9: Corum Board
Corum Board Nick England Dennis Bastas Jon Newberry Jayne Shaw Julian Sallabank Chairman Non-Executive Director Non-Executive Director Non-Executive Director CEO & Managing Director ➢ 35 years of senior ➢ Majority shareholder ➢ 30 years experience ➢ Executive roles in two ➢ Managing Director and exe
Slide 10: A Year of Consolidation
A Year of Consolidation Revenue & EBITDA Agreements with Key Key Appointments PharmX Growth Retail Groups Corum Group grew Dennis Bastas joined the Growth of suppliers Agreements struck with revenues by 26% and Board end of 2020. connected to the PharmX large retail groups including underlying EBITD
Slide 11: A Year of Consolidation
A Year of Consolidation Innovation Payments Partnership Growth Cyber Security Innovative new services Introduction of payments Enhanced partnership with Launched CyberGuard, developed to drive capabilities – an extension Sigma via the WholeLife subscription-based service efficiencies. of our orderin
Slide 12: CEO Update
CEO Update
Slide 13: Strategy Update
Strategy Update Align Products, Create competitive Maintain a lean Retain and Expand advantage across operating model Customers the Group Disciplined approach to cost control Product alignment strategy led to We have a clear strategy for delivered efficiencies. the retirement of our legacy PharmX: C
Slide 14: What we have delivered
What we have delivered Revenue Growth EBITDA Margin Enhanced Team PharmX Total revenue for FY21 Significant uplift in EBITDA Management restructure Increase in suppliers and $13.4M. margin to 35%. completed during the year. connections of 9%. Health revenue increased Underlying EBITDA $4.4M Industry
Slide 15: Looking Ahead
Looking Ahead Team Culture, Customers and Shareholder Returns Creating new Increasing workflow efficiencies and adding value to all revenue streams stakeholders. Delivered via Cyber, Data, Payments and improved market place accessibility and connectivity. Focus on Delivering on our Additional Increa
Slide 16: Appendix
Appendix
Slide 17: Profit & Loss
Profit & Loss Profit & Loss (A$000's) H1'20 H2'20 FY'20 H1'21 H2'21 FY21 ∆ PCP Revenue $5,011 $5,632 $10,643 $6,642 $6,740 $13,382 26% Health $4,056 $4,763 $8,819 $5,862 $6,013 $11,875 34.7% eCommerce $955 $869 $1,824 $780 $727 $1,507 -17.4% Expenses Materials and consumables ($574) ($629) ($1,203)
Slide 18: Balance Sheet
Balance Sheet Balance Sheet (A$000's) FY'20 FY'21 Current assets Cash and cash equivalents $2,323 $6,478 Trade and other receivables $3,826 $864 Inventories $64 $34 Income tax receivable $1,700 $1,548 Other assets $1,928 $1,492 Total $9,841 $10,416 Non-current assets Investments $2,686 - Property, p
Slide 19: Cashflow
Cashflow Cash flow (A$000's) FY’20 FY’21 Cash flows from operating activities Receipts from customers $9,773 $13,887 Payments to suppliers and employees ($11,238) ($12,534) Interest and other revenue received $341 $108 Income tax paid ($281) ($272) Research and development incentive $1,774 $1,973 Ne
Slide 20: Corum Group Limited Contact
Corum Group Limited Contact: Investor.Relations@corum.com.au